Hartmut Juhl

Indivumed GmbH engages in the research and development of medical treatment for cancer patients. The firm develops an integrated analytical platform, which links sample sets from cancer patients such as tissue types, serum, plasma, and urine with a web-accessible database. It offers treatment for the people suffering from GI-tract such as colorectal, gastric, pancreatic, breast, and lung cancer. The company was founded by Hartmut Juhl, Carsten Zornig and Peter Layer in April 2002 and is headquartered in Hamburg, Germany.

Indivumed GmbH engages in the research and development of medical treatment for cancer patients. The firm develops an integrated analytical platform, which links sample sets from cancer patients such as tissue types, serum, plasma, and urine with a web-accessible database. It offers treatment for the people suffering from GI-tract such as colorectal, gastric, pancreatic, breast, and lung cancer. The company was founded by Hartmut Juhl, Carsten Zornig and Peter Layer in April 2002 and is headquartered in Hamburg, Germany.

Indivumed GmbH engages in the research and development of medical treatment for cancer patients. The firm develops an integrated analytical platform, which links sample sets from cancer patients such as tissue types, serum, plasma, and urine with a web-accessible database. It offers treatment for the people suffering from GI-tract such as colorectal, gastric, pancreatic, breast, and lung cancer. The company was founded by Hartmut Juhl, Carsten Zornig and Peter Layer in April 2002 and is headquartered in Hamburg, Germany.

Indivumed GmbH engages in the research and development of medical treatment for cancer patients. The firm develops an integrated analytical platform, which links sample sets from cancer patients such as tissue types, serum, plasma, and urine with a web-accessible database. It offers treatment for the people suffering from GI-tract such as colorectal, gastric, pancreatic, breast, and lung cancer. The company was founded by Hartmut Juhl, Carsten Zornig and Peter Layer in April 2002 and is headquartered in Hamburg, Germany.

Indivumed GmbH engages in the research and development of medical treatment for cancer patients. The firm develops an integrated analytical platform, which links sample sets from cancer patients such as tissue types, serum, plasma, and urine with a web-accessible database. It offers treatment for the people suffering from GI-tract such as colorectal, gastric, pancreatic, breast, and lung cancer. The company was founded by Hartmut Juhl, Carsten Zornig and Peter Layer in April 2002 and is headquartered in Hamburg, Germany.

Indivumed GmbH engages in the research and development of medical treatment for cancer patients. The firm develops an integrated analytical platform, which links sample sets from cancer patients such as tissue types, serum, plasma, and urine with a web-accessible database. It offers treatment for the people suffering from GI-tract such as colorectal, gastric, pancreatic, breast, and lung cancer. The company was founded by Hartmut Juhl, Carsten Zornig and Peter Layer in April 2002 and is headquartered in Hamburg, Germany.

Indivumed GmbH engages in the research and development of medical treatment for cancer patients. The firm develops an integrated analytical platform, which links sample sets from cancer patients such as tissue types, serum, plasma, and urine with a web-accessible database. It offers treatment for the people suffering from GI-tract such as colorectal, gastric, pancreatic, breast, and lung cancer. The company was founded by Hartmut Juhl, Carsten Zornig and Peter Layer in April 2002 and is headquartered in Hamburg, Germany.